MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT), announced today that it has received CE (Conformité Européene) Mark approval for the commercial sale of the Endeavor® Resolute Drug-Eluting Coronary Stent and plans to launch the product outside the United States earlier than originally projected.
The Endeavor Resolute stent will be launched in more than 50 countries in Europe, Asia, the Middle East and Africa by the end of 2007 – making Medtronic the first company to offer two internally developed drug-eluting stent options for the treatment of coronary artery disease, a condition affecting millions of people worldwide. The new stent is not approved in the United States.
